Multi-Agent Antiviral Therapy for Coronavirus Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, such as COVID-19, lack effective therapies beyond existing antiviral drugs, necessitating the development of additional treatments that target multiple stages of the coronavirus life cycle to combat severe respiratory syndromes and mutations.
Innovation Solution
Administration of a therapeutically effective amount of agents like artesunate, dihydroartemisinin, isorhamnetin, lycorine, (+)-taxifolin, baicalin, tashinone I, and desethylamodiaquine, potentially in combination with other agents like remdesivir or camostat, to target various stages of the coronavirus life cycle, including viral attachment, penetration, and replication, while downregulating cytokine production and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral therapeutics (PAXLOVID, LAGEVRIO, remdesivir, bebtelovimab) are used to treat coronavirus infection, then viral replication is inhibited, but drug resistance develops and treatment options are limited
Solution Approach 1:
The patent divides the antiviral treatment into multiple independent agents, each targeting different stages of the coronavirus life cycle. The first agent targets viral attachment/entry, the second agent targets replication, and the third agent targets assembly/release. This segmentation allows each agent to be optimized for its specific target while collectively providing comprehensive coverage of the viral life cycle, preventing any single mutation from conferring resistance to all agents.
Solution Approach 2:
The patent employs a multi-functional treatment approach where the combination of agents addresses multiple functions: inhibiting viral entry, blocking replication, preventing assembly/release, and modulating host immune response. This multi-functionality ensures that the treatment remains effective against various coronavirus strains and mutations by covering all critical stages of the viral life cycle.
2Ease of operation
If a single antiviral agent is used to treat coronavirus infection, then the treatment protocol is simple, but the virus can mutate and develop resistance
Solution Approach 1:
The patent merges multiple antiviral agents with different mechanisms of action into a single combination therapy regimen. By combining agents that target different stages of the viral life cycle, the treatment maintains simplicity in administration (oral or injectable routes) while achieving reliable resistance prevention through multi-target inhibition. The agents work synergistically to block viral propagation at multiple points simultaneously.
Solution Approach 2:
The patent creates a composite therapeutic regimen combining chemically distinct agents with complementary mechanisms of action. This composite approach integrates agents that interfere with viral attachment, replication, and assembly processes, forming a robust treatment strategy that prevents resistance development while maintaining operational simplicity through coordinated administration.
3Reliability
If multiple agents are administered to target different stages of coronavirus life cycle, then drug resistance is reduced, but the treatment complexity increases
Solution Approach 1:
The patent segments the antiviral strategy into distinct functional modules, each represented by an agent targeting a specific stage of the viral life cycle. This segmentation allows for systematic optimization of each agent's mechanism while maintaining overall regimen manageability. The modular structure facilitates clear understanding of each agent's role and simplifies monitoring of treatment response.
Data Source
AI summary
Methods for treating a coronavirus infection in a subject, which include administering to the subject a therapeutically effective amount of an agent selected from one or more of artesunate, dihydroartemisinin, isorhamnetin, lycorine, (+)-taxifolin, baicalin, tashinone I, and desethylamodiaquine. Pharmaceutical compositions including in a pharmaceutically acceptable carrier, two or more agents selected from the group consisting of artesunate, dihydroartemisinin, isorhamnetin, lycorine, (+)-taxifolin, baicalin, tashinone I, desethylamodiaquine, artemisinin, nirmatrelvir and ritonavir, nirmatrelvir, ritonavir, baicalein, rhamnetin, (−)-taxifolin, and cryptotanshinone.